Two new antithrombin variants support a role for K114 and R13 in heparin binding

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 2, 2003, Pages 386-387

  Picard, V ^a   Susen, S ^b   Bellucci, S ^c   Aiach, M ^a   Alhenc Gelas, M ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN;

ADULT; AMINO ACID SUBSTITUTION; BINDING SITE; BLOOD; CASE REPORT; CHEMISTRY; FEMALE; GENETIC VARIABILITY; GENETICS; HETEROZYGOTE; HUMAN; IN VITRO STUDY; LETTER; METABOLISM; RISK FACTOR; THROMBOSIS;

ADULT; AMINO ACID SUBSTITUTION; ANTITHROMBINS; BINDING SITES; FEMALE; HEPARIN; HETEROZYGOTE; HUMANS; RISK FACTORS; THROMBOSIS; VARIATION (GENETICS);

EID: 0141785241     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00048.x     Document Type: Letter

References (7)

1. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87: 34S-38S.
2. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 197-211.
3. Picard V, Bura A, Emmerich J, Alhenc-Gelas M, Biron C, Houbouyan-Reveillard LL, Molho P, Labatide-Alanore A, Sie P, Toulon P, Verdy E, Aiach M. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br J Haematol 2000; 110: 731-4.
4. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-8.
5. Ersdal-Badju E, Lu A, Zuo Y, Picard V, Bock SC. Identification of the antithrombin III heparin binding site. J Biol Chem 1997; 272: 19393-400.
6. Kridel SJ, Knauer DJ. Lysine residue 114 in human antithrombin III is required for heparin pentasaccharide-mediated activation. J Biol Chem 1997; 272: 7656-60.
7. Arocas V, Bock SC, Raja S, Olson ST, Bjork I. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 2001; 276: 43809-17.